Supriya Lifescience

Supriya Lifescience Diluted EPS

The Diluted Earnings per Share of Supriya Lifescience (SUPRIYA.NS) as of Oct 16, 2026 is 26.01 INR. In the previous year, Diluted Earnings per Share was 23.35 INR — a change of 11.40% (higher).

Diluted EPS

26.01INR

YoY

11.40%

Last updated:

Diluted Earnings per Share of Supriya Lifescience is 2026 26.01 INR. Diluted Earnings per Share of Supriya Lifescience was 2025 23.35 INR. It decreases by 11.40% higher compared to the previous year.

The Supriya Lifescience Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2019
4.90 INR
Jan 1, 2020
28.73 INR
Jan 1, 2021
15.37 INR
Jan 1, 2022
18.86 INR
Jan 1, 2023
11.16 INR
Jan 1, 2024
14.82 INR
Jan 1, 2025
23.35 INR
Jan 1, 2026
26.01 INR
The Supriya Lifescience Diluted EPS history
YEARDiluted EPSYoY
26.01INR+11.40%
23.35INR+57.55%
14.82INR+32.72%
11.16INR-40.81%
18.86INR+22.71%
15.37INR-46.50%
28.73INR+486.04%
4.90INR+351.70%
1.09INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Supriya Lifescience Stock analysis

What does Supriya Lifescience do? Supriya Lifescience Ltd is a pharmaceutical company based in Mumbai, India, operating within the healthcare sector. The company specializes in the research, development, and manufacturing of active pharmaceutical ingredients (APIs), with a focus on niche therapeutic segments. It employs 392 full-time staff and completed its initial public offering (IPO) on December 28, 2021. The firm's manufacturing facilities are located in Maharashtra, and it exports products to approximately 86 countries. Its product portfolio includes APIs for antihistamines, anesthetics, anti-asthma treatments, and other therapeutic areas such as analgesics and vitamins. Specific products mentioned include Chlorphenamine Maleate, Pheniramine Maleate, Brompheniramine Maleate, Dexchlorpheniramine Maleate, Mepyramine / Pyrilamine Maleate, Dexbrompheniramine Maleate, Cetirizine DiHCL, Diphenhydramine HCL, Bisoprolol Fumarate, Nicorandil, Mecobalamin, Hydroxocobalamin Sulphate, Hydroxocobalamin Acetate, and Hydroxocobalamin Hydrochloride. The company is engaged in the production of bulk drugs and pharmaceutical chemicals, serving global markets through its export activities. It operates with a focus on niche API products, addressing specific therapeutic needs across multiple categories. The company's website is https://supriyalifescience.com/. Supriya Lifescience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Supriya Lifescience stock

Diluted Earnings per Share of Supriya Lifescience is 26.01 INR in 2026.

Diluted Earnings per Share of Supriya Lifescience changed from 23.35 INR to 26.01 INR, representing a 11.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share Supriya Lifescience since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Supriya Lifescience

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Supriya Lifescience